 |
5 Diseases |  |
20 Trials |
|
20 Trials |  |
1129 News |  |
| «12345678910111213 |
- ||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women (clinicaltrials.gov) - Jul 14, 2015
P3, N=436, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis (clinicaltrials.gov) - May 16, 2015
P2, N=252, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Apr 10, 2015
P3, N=4094, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed: BRIDGE: A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis (clinicaltrials.gov) - Apr 6, 2015
P3, N=245, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial primary completion date: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jan 30, 2015
P3, N=4000, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Apr 2017
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: BRIDGE: A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis (clinicaltrials.gov) - Jul 12, 2014
P3, N=225, Recruiting, Sponsor: Amgen
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial primary completion date: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women (clinicaltrials.gov) - May 19, 2014
P3, N=436, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2017 --> Apr 2017 Trial primary completion date: Mar 2015 --> Apr 2015
- ||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women (clinicaltrials.gov) - May 19, 2014
P3, N=436, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2015 --> Apr 2015 Recruiting --> Active, not recruiting
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion date: Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density (clinicaltrials.gov) - May 8, 2014
P2, N=419, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial completion date: Mar 2014 --> Apr 2016
- ||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed, Head-to-Head: A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Apr 14, 2014
P3, N=294, Active, not recruiting, Sponsor: Amgen
Trial completion date: Mar 2014 --> Apr 2016 Recruiting --> Active, not recruiting
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion, Metastases: Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis (clinicaltrials.gov) - Apr 13, 2014
P1, N=24, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed: FRAME: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Mar 2, 2014
P3, N=7180, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial, Head-to-Head: A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Dec 18, 2013
P3, N=294, Active, not recruiting, Sponsor: Amgen
- ||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P2 trial: Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis (clinicaltrials.gov) - Nov 21, 2013
P2, N=252, Active, not recruiting, Sponsor: Amgen
- ||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: Transition From Alendronate to Romosozumab (AMG 785) (clinicaltrials.gov) - Oct 9, 2013
P1, N=60, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment open: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jul 7, 2013
P3, N=4000, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Ongoing --> Recruiting
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial, Metastases: Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis (clinicaltrials.gov) - Apr 15, 2013
P1, N=24, Completed, Sponsor: Amgen
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial: A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) (clinicaltrials.gov) - Apr 4, 2013
P1, N=48, Completed, Sponsor: Amgen
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: Study To Assess FRacTure Healing With SclerosTin Antibody - Hip (clinicaltrials.gov) - Mar 24, 2013
P2, N=332, Completed, Sponsor: Amgen
Ongoing --> Recruiting Recruiting --> Completed
- |||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial completion: Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing (clinicaltrials.gov) - Mar 10, 2013
P2, N=402, Completed, Sponsor: Amgen
Recruiting --> Completed Recruiting --> Completed
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women (clinicaltrials.gov) - Feb 19, 2013
P3, N=400, Recruiting, Sponsor: Amgen
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: ARCH: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Jun 27, 2012
P3, N=4000, Recruiting, Sponsor: Amgen
- ||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial: Transition From Alendronate to Romosozumab (AMG 785) (clinicaltrials.gov) - Apr 29, 2012
P1, N=60, Completed, Sponsor: Amgen
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P3 trial: FRAME: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Apr 10, 2012
P3, N=7180, Active, not recruiting, Sponsor: Amgen